Free Trial
NASDAQ:PRPO

Precipio Q1 2024 Earnings Report

Precipio logo
$6.03 -0.70 (-10.40%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$6.14 +0.11 (+1.82%)
As of 04/25/2025 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precipio EPS Results

Actual EPS
-$1.46
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Precipio Revenue Results

Actual Revenue
$3.43 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Precipio Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Precipio's next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules.

Precipio Earnings Headlines

Precipio trading halted, volatility trading pause
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Precipio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precipio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precipio and other key companies, straight to your email.

About Precipio

Precipio (NASDAQ:PRPO), a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

View Precipio Profile

More Earnings Resources from MarketBeat